Search

Displaying results 6561 - 6570 of 10000 in total
  1. Drug

    Iron isomaltoside 1000

    go.drugbank.com/drugs/DB12208
    ApprovedInvestigationalWithdrawn

    Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia.

  2. Drug

    Bifunctional epoxide hydrolase 2

    go.drugbank.com/drugs/DB15139
    Investigational

    Bifunctional epoxide hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients … With Heart Failure, and in Healthy Volunteers).

  3. Drug

    Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16924
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  4. Drug

    Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17751
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  5. Drug

    Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17994
    Approved

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB17997
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB19320
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB22670
    Approved

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB22672
    Approved

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. … CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain.